Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
Juric D, Barve M, Vaishampayan U, Roda D, Calvo A, Jañez NM, Trigo J, Greystoke A, Harvey RD, Olszanski AJ, Opyrchal M, Spira A, Thistlethwaite F, Jiménez B, Sappal JH, Kannan K, Riley J, Li C, Li C, Gregory RC, Miao H, Wang S. Juric D, et al. Among authors: janez nm. Cancer Med. 2024 Mar;13(5):10.1002/cam4.6776. doi: 10.1002/cam4.6776. Cancer Med. 2024. PMID: 38501219 Free PMC article. Clinical Trial.
A guide to the use of bioassays in exploration of natural resources.
Sabotič J, Bayram E, Ezra D, Gaudêncio SP, Haznedaroğlu BZ, Janež N, Ktari L, Luganini A, Mandalakis M, Safarik I, Simes D, Strode E, Toruńska-Sitarz A, Varamogianni-Mamatsi D, Varese GC, Vasquez MI. Sabotič J, et al. Among authors: janez n. Biotechnol Adv. 2024 Mar-Apr;71:108307. doi: 10.1016/j.biotechadv.2024.108307. Epub 2024 Jan 5. Biotechnol Adv. 2024. PMID: 38185432 Free article. Review.
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
Bardia A, Jhaveri K, Kalinsky K, Pernas S, Tsurutani J, Xu B, Hamilton E, Im SA, Nowecki Z, Sohn J, Laurentiis M, Jañez NM, Adamo B, Lee KS, Jung KH, Rubovszky G, Tseng LM, Lu YS, Yuan Y, Maxwell MJ, Haddad V, Khan SS, Rugo HS, Pistilli B. Bardia A, et al. Among authors: janez nm. Future Oncol. 2024 Mar;20(8):423-436. doi: 10.2217/fon-2023-0188. Epub 2023 Jun 30. Future Oncol. 2024. PMID: 37387213 Free article.
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Schmid P, Cortes J, Joaquim A, Jañez NM, Morales S, Díaz-Redondo T, Blau S, Neven P, Lemieux J, García-Sáenz JÁ, Hart L, Biyukov T, Baktash N, Massey D, Burris HA 3rd, Rugo HS. Schmid P, et al. Among authors: janez nm. Breast Cancer Res. 2023 Jun 12;25(1):67. doi: 10.1186/s13058-023-01649-w. Breast Cancer Res. 2023. PMID: 37308971 Free PMC article. Clinical Trial.
Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study.
Villarroel PG, Padró JG, Marquina G, Jáñez NM, González EE, Antón A, Sánchez MB, Cáceres AR, López-López R, Cornejo RE, García PB, Fabregat RM, Fernández BC, Bermudo CL, Camps C. Villarroel PG, et al. Among authors: janez nm. Future Oncol. 2022 Nov;18(35):3913-3927. doi: 10.2217/fon-2022-0758. Epub 2022 Dec 20. Future Oncol. 2022. PMID: 36537885 Free article.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Geyer CE Jr, et al. Ann Oncol. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10. Ann Oncol. 2022. PMID: 36228963 Free PMC article. Clinical Trial.
Listeria innocua Biofilm Assay Using NanoLuc Luciferase.
Berlec A, Janež N, Sterniša M, Klančnik A, Sabotič J. Berlec A, et al. Among authors: janez n. Bio Protoc. 2022 Feb 5;12(3):e4308. doi: 10.21769/BioProtoc.4308. eCollection 2022 Feb 5. Bio Protoc. 2022. PMID: 35284607 Free PMC article.
31 results